You searched for mRNA Therapeutics - Page 3 of 20

News and Trends 10 Aug 2022

Aro Biotherapeutics gets FDA orphan drug designation for treatment of Pompe Disease

Aro Biotherapeutics says the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ABX1100, an investigational Centyrin-siRNA conjugate that targets the Gys1 gene in the muscle, for the treatment of Pompe disease. “We are pleased to have received this designation and are gratified by the FDA’s recognition of the potential of ABX1100 […]

August 10, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Jul 2022

Cancer therapeutics company’s double win with $25M funding, and appointment of new board member

An mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — this week announced the completion of a $25 million Series A financing. Kernal Biologics, Inc. (Kernal Bio) confirmed that the funding was led by Hummingbird Ventures. Amgen Ventures, HBM Genomics and Civilization Ventures along with other venture capitalists, family offices and […]

July 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 6 Jul 2022

Exyte Builds mRNA Competence Center for WACKER in Germany

A messenger ribonucleic acid (mRNA) competence center is being built at the Halle Biotech site of German company Wacker Chemie AG (WACKER). Exyte GmbH is a global design, engineering company that delivers facilities for high-tech industries and is in charge of the site at WACKER. The project is making a considerable contribution towards strengthening the […]

July 6, 2022 - 4 minutesmins - By Liza Laws

In Depth 4 Jul 2022

The COVID-19 pandemic has driven RNA therapeutics into the mainstream

As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit for rare diseases, the field of RNA therapeutics is now moving faster than ever before. The COVID-19 pandemic proved a turning point for the biotech companies BioNTech and Moderna, which specialize in developing technology based on messenger RNA (mRNA). The […]

July 4, 2022 - 8 minutesmins - By Helen Albert

ethris mrna therapy respiratory infection

News and Trends 1 Feb 2022

Ethris Raises €23M to Make Inhaled Respiratory Therapies from mRNA

Thanks to Covid-19 vaccines, messenger RNA (mRNA) technology has reached the mainstream. With a €23.4M Series B round, the German firm Ethris is riding the mRNA buzz by developing inhalable mRNA therapies for respiratory diseases. As Covid-19 mRNA vaccines entered the market for the first time in 2020, the wide potential of mRNA technology became […]

February 1, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 17 Aug 2021

Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology

Sanofi’s acquisition of its partner Translate Bio is a clear sign that pharmaceutical companies are interested in messenger RNA technologies beyond Covid-19. Based in Boston, US, Translate Bio develops mRNA therapies for a range of conditions, including respiratory, liver, and infectious diseases. The company’s €2.7B ($3.2B) buyout, announced by Sanofi earlier this month, seems a […]

August 17, 2021 - 5 minutesmins - By Mark Zipkin

Ziphius Vaccines Covid 19 pandemic vaccine treatment

News and Trends 1 Jun 2021

Next-Generation mRNA Vaccine Technology Unveiled in Series A Round

Messenger RNA vaccines have been at the forefront of the global struggle against the Covid-19 pandemic over the past year. Now scientists are working to upgrade the technology: enter the stage of saRNA, or self-amplifying RNA vaccines. Among the frontrunners to introduce saRNA technology is the Belgian startup Ziphius Vaccines, which recently raised €29.3M to […]

June 1, 2021 - 4 minutesmins - By Victor Kotsev

neoantigen immuno oncology cancer therapy achilles therapeutics

News and Trends 15 Apr 2021

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed starter pistol for investments into neoantigen-based therapies, a family of personalized cancer immunotherapies that target proteins unique to an individual’s tumor. Neoantigen-focused companies have closed smaller initial public offerings (IPOs) in the past. Two major […]

April 15, 2021 - 5 minutesmins - By Mark Zipkin

mRNA DNA race Covid 19 vaccine BioNTech Pfizer

News and Trends 22 Dec 2020

EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19

BioNTech and Pfizer’s Covid-19 vaccine, made from messenger RNA, has become the first of its kind to be approved by the EMA. The EMA has granted conditional approval to Comirnaty, a vaccine against Covid-19 developed by BioNTech and Pfizer. The approval comes weeks after the UK became the first country in the world to approve […]

December 22, 2020 - 5 minutesmins - By Jonathan Smith

News and Trends 19 Nov 2020

mRNA Stocks Soar with Final Results of BioNTech’s Covid-19 Vaccine

The field of messenger RNA therapeutics is flying high as BioNTech and Pfizer conclude a phase III trial with their Covid-19 vaccine showing 95% effectiveness. The phase III trial recruited over 43,000 volunteers to gauge whether Covid-19 infections could be prevented by a vaccine made out of messenger RNA (mRNA). One group received two doses […]

November 19, 2020 - 6 minutesmins - By Jonathan Smith

News and Trends 23 Jul 2020

Pharma Giant GSK and mRNA Biotech CureVac Ink €1B Deal

GlaxoSmithKline (GSK) has struck a deal worth up to €1B with the German biotechnology company CureVac to co-develop messenger RNA drugs for infectious diseases. Under the terms of the deal, GSK will fund the development and manufacturing of up to five mRNA-based vaccines and antibody drugs targeting undisclosed infectious diseases. CureVac’s current rabies and Covid-19 […]

July 23, 2020 - 3 minutesmins - By David Wilson

BioNTech Production scaled e1584385495951

News and Trends 29 Apr 2020

Update: BioNTech and Pfizer’s mRNA Vaccine for Covid-19 Tested in Humans

Update (29/04/2020): A vaccine developed by the German company BioNTech and its big pharma partner Pfizer has become the first European mRNA vaccine for Covid-19 to enter human testing in a phase I/II trial. Since dosing began last week, twelve volunteers in Germany have been given the vaccine. The first part of the trial — […]

April 29, 2020 - 5 minutesmins - By Helen Albert

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us